|
| |
We are a dynamic and creative company who has evolved our business model to meet the changing needs of the life science industry. |
|
Letter from CEO...
|
|
| |
| Investment Summary |
| Industry sector: |
|
Therapeutics (biologics, NCE, orphan), med-tech, device/diagnostic |
| Size of investment: |
|
Seed Funding to Series C |
| Investment stage: |
|
Phase I-IV clinical trial |
| Return on investment: |
|
Equity, downstream royalties, milestone payments, etc. |
| Geography: |
|
UK and rest of EU, US, Israel, etc. |
|
|
|
|
| |
